Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel Schedules in Elderly Men with mCRPC (CABASTY)
NCT02961257Phase 3Completed
- Sponsor
- ARTIC
- Start
- May 2017
- Primary completion
- Dec 2021
- Modality
- Allosteric Modulators
- Countries
- 2
01
Overview
A Phase 3 trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by ARTIC. Started May 2017; status: completed.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02961257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961257.